ENB Therapeutics is a pioneering biotech company based in New York, NY, dedicated to revolutionizing cancer therapy by overcoming immunotherapy resistance. Their innovative approach targets critical components in the tumor microenvironment, empowering the body's immune system to effectively combat drug-resistant cancers.
With a focus on switching tumors from "cold" to "hot" and creating new intratumoral tertiary lymphoid organs (TLOs), ENB Therapeutics aims to unlock the effectiveness of cancer therapies in the most challenging-to-treat tumors. Their small molecules turn off the ETBR switch, enabling immune cells to infiltrate and kill tumors, while promoting the formation of TLOs that produce tumor-specific T- and B-cells, leading to long-lasting anti-cancer immunity.
Generated from the website